

List of publications: Equipe KAVERI

Original articles in peer reviewed journals (from 2007 onwards)

1. Dasgupta S, Repesse Y, Bayry J, Navarrete AM, Wootla B, Delignat S, Irinopoulou T, Kamate C, Saint-Remy JM, Jacquemin M, Lenting PJ, Borel-Derlon A, Kaveri SV, Lacroix-Desmazes S. 2007. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. *Blood* 109: 610-612
2. Dasgupta S, Navarrete, AM, Bayry J, Delignat S, Wootla B, André S, Christophe O, Nascimbeni M, Jacquemin M, Martinez-Pomares L, Geijtenbeek TBH, Moris A, Saint-Remy JM, Kazatchkine MD, Kaveri SV and Lacroix-Desmazes S. 2007. A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. *Proc Natl Acad Sci. USA* 104:8965-8970.
3. Bayry J, Triebel F, Kaveri SV and Tough DF. (2007). Human dendritic cells acquire a semi-mature phenotype and lymph node homing potential through interaction with regulatory T cells. *J Immunol.* 178: 4184-4193
4. Bayry J, Kaveri SV and Tough D. 2007. Do activated human dendritic cells diminish the suppressive functions of regulatory T cells? *Arthritis Rheum* 56:3874-6
5. Dimitrov JD, Roumenina LT, Doltchinkova VR, Mihaylova NM, Lacroix-Desmazes S, Kaveri SV, Vassilev TL. 2007. Antibodies use heme as a cofactor to extend their pathogen elimination activity and to acquire new effector functions *J Biol Chem.* 282:26696-706
6. Groyer E, Nicoletti A, Ait-Oufella H, Khallou-Laschet J, Varthaman A, Gaston AT, Thaunat O, Kaveri SV, Blatny R, Stockinger H, Mallat Z, Caligiuri G. 2007. Atheroprotective effect of CD31 receptor globulin through enrichment of circulating regulatory T-cells. *J Am Coll Cardiol.* 2007 24;50:344-350
7. Caligiuri G, Khallou-Laschet J, Vandaele M, Gaston AT, Delignat S, Mandet C, Kohler HV, Kaveri SV, Nicoletti A. 2007. Phosphorylcholine-targeting immunization reduces atherosclerosis. *J Am Coll Cardiol.* 50:540-546.
8. Dimitrov JD, Lacroix-Desmazes S, Kaveri SV, Vassilev TL. 2007. Transition towards antigen-binding promiscuity of a monospecific antibody. *Mol Immunol.* 44: 1854-63
9. Rajagopalan G, Patel R, Kaveri SV, David CS. 2007. Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation. *J Antimicrob Chemother.* 59: 157-9
10. Lavigne-Lissalde G, Lacroix-Desmazes S, Wootla B, Tarrade C, Schved JF, Kaveri SV, Granier C, Villard-Saussine S. 2007. Molecular characterization of human B domain-specific anti-factor VIII monoclonal antibodies generated in transgenic mice. *Thromb Haemost.* 98:138-47.
11. Delignat, S., Dasgupta, S., André, S., Navarrete, A.M., Bayry, J., Kaveri, S.V., André, M.H., Chtourou, S., Tellier, Z. and Lacroix-Desmazes, S. 2007. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.

Haematologica 92: 1423-1426.

12. McGready R, Kaveri SV, Lacroix-Desmazes S, Krudsood S, Newton PN. (2007). Acquired haemophilia A in early pregnancy associated with Plasmodium vivax malaria and hyperthyroidism. *Aust N Z J Obstet Gynaecol.* 47:76-7
13. Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, Delignat S, Elluru S, Bayry J, Lacroix-Desmazes S, Cohen JL, Salomon BL, Kazatchkine MD, Kaveri SV, Misra N. 2008. Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. *Blood* 111:715-22.
14. Dasgupta S, Navarrete AM, André S, Wootla B, Delignat S, Repessé Y, Bayry J, Nicoletti A, Saenko EL, d'Oiron R, Jacquemin M, Saint-Remy JM, Kaveri SV, Lacroix-Desmazes S. 2008. Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation. *Haematologica* 93:83-9.
15. Servettaz A, Guilpain P, Camoin L, Mayeux P, Broussard C, Tamby MC, Tamas N, Kaveri SV, Guillemin L, Mouthon L. 2008. Identification of target antigens of antiendothelial cell antibodies in healthy individuals: A proteomic approach. *Proteomics* 8:1000-1008
16. Wootla, S. Dasgupta, J. D Dimitrov, J. Bayry, H. Lévesque, J-Y. Borg, A. Borel-Derlon, D. N. Rao, A. Friboulet, S. V. Kaveri, S. Lacroix-Desmazes. 2008. FVIII hydrolysis mediated by anti-FVIII autoantibodies in acquired hemophilia. *J. Immunol* 180(11):7714-20.
17. Wootla, B., A. Nicoletti, N. Patey, J. D. Dimitrov, C. Legendre, O. D. Christophe, A. Friboulet, S. V. Kaveri, S. Lacroix-Desmazes and O. Thaumat. 2008. IgG-mediated hydrolysis of coagulation factors is associated with a reduced risk for chronic allograft nephropathy in renal transplanted patients. *J. Immunol.* 180:8455-60.
18. Bayry J, Tchilian EZ, Davies MN, Forbes EK, Draper SJ, Kaveri S, Hill AVS, Kazatchkine MD, Beverley PCL, Flower DR and Tough DF. 2008. In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination. *Proc Natl Acad Sci. USA.* 105: 10221-10226.
19. Elluru, S., J.P. Duong Van Huyen, S. Delignat, M D Kazatchkine, A. Friboulet, S. V Kaveri and J. Bayry. 2008. Induction of maturation and activation of human dendritic cells: A mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer. *BMC Cancer* 8:161.
20. Clauce-Coupe H, Chateau S, Ducrocq C, Niot V, Kaveri S, Dubois F, Sangwan-Norreel B, Sangwan RS. 2008. Role of vitronectin-like protein in Agrobacterium attachment and transformation of Arabidopsis cells. *Protoplasma* 234:65-75
21. Mihaylova N, Voynova E, Tchobanov A, Dolashka-Angelova P, Bayry J, Devreese B, Kaveri SV and Vassilev T. 2009. Simultaneous engagement of FcγIIb and CD22 inhibitory receptors silences targeted B cells and suppresses autoimmune disease activity. *Mol Immunol.* 47:123-130.
22. Djoumerska-Alexieva, I.K. J.D. Dimitrov, J. Nacheva, S.V. Kaveri and T. Vassilev. 2009. Protein destabilizing agents induce polyreactivity and enhanced immunomodulatory activity in ivig preparations. *Autoimmunity.* 42:365-7.

23. Bayry J, Bansal K, Kazatchkine MD and Kaveri S. 2009. DC-SIGN and $\alpha 2,6$ -sialylated IgG Fc interaction is dispensable for the anti-inflammatory activity of IVIg on human dendritic cells. *Proc Natl Acad Sci. USA*. 106:E24.
24. Elluru SR, Van Huyen JP, Delignat S, Prost F, Heudes D, Kazatchkine MD, Friboulet A, Kaveri SV. 2009. Antiangiogenic properties of viscum album extracts are associated with endothelial cytotoxicity. *Anticancer Res*. 29:2945-50.
25. Aimanianda V, Bayry, J, Bozza S, Knemeyer O, Perruccio K, Elluru SR, Clavaud C, Paris S, Brakhage AA, Kaveri SV, Romani L and Latgé JP. 2009. Surface hydrophobin prevents immune recognition of airborne fungal spores. *Nature* 460: 1117-1121.
26. Bussone G, Dib H, Dimitrov JD, Camoin L, Broussard C, Tamas N, Guillemin L, Kaveri SV, Mouthon L. 2009. Identification of target antigens of self-reactive IgG in intravenous immunoglobulin preparations. *Proteomics* 9:2253-62.
27. Navarrete AM, Meslier Y, Teyssandier M, André S, Delignat S, Triebel S, Kaveri SV, Lacroix-Desmazes S, Bayry J. 2009. CD4+CD25+ regulatory T cells modulate human dendritic cell chemokines by multiple mechanisms. *Arthritis Rheum*. 60: 2848-2849.
28. Vani J, Shaila MS, Rao MK, Krishnaswamy UM, Kaveri SV and Bayry J. 2009. B lymphocytes from tuberculosis patients exhibit hampered antigen-specific responses with a concomitant over-expression of IL-8. *J Infect Dis*. 200: 481-482
29. Navarrete A, Dasgupta S, Delignat S, Caligiuri G, Christophe OD, Bayry J, Nicoletti A, Kaveri SV, Lacroix-Desmazes S. 2009. Splenic marginal zone antigen presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A. *J Thromb Haemost*. 7: 1816-1823.
30. Metlas RM, Srdic TV, Jenabian MA, Elluru S, Carta L, Bowker TJ, Kaveri SV, Concas D. 2009. Immunoglobulin G-reactive antibodies from sera of healthy individuals enriched in IgG2--therapeutic potential in HIV-1 infection. *Curr HIV Res*. 7:378-83.
31. Roumenina LT, Jablonski M, Hue C, Blouin J, Dimitrov JD, Dragon-Durey MA, Cayla M, Fridman WH, Macher MA, Ribes D, Moulouquet L, Rostaing L, Satchell SC, Mathieson PW, Sautes-Fridman C, Loirat C, Regnier CH, Halbwachs-Mecarelli L, Fremeaux-Bacchi V. 2009. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. *Blood* 114:2837-45.
32. Davies MN, Bayry J, Tchilian EZ, Vani J, Shaila MS, Forbes EK, Draper SJ, Beverley PCL, Tough DF, Flower DR. 2009. Toward the discovery of vaccine adjuvants: Coupling *in silico* screening and *in vitro* analysis of antagonist binding to human and mouse CCR4 receptors. *PLoS ONE* 4:e8084.
33. Wootla B, Mahendra A, Dimitrov JD, Friboulet A, Borel-Derlon A, Rao DN, Uda T, Borg JY, Bayry J, Kaveri SV and Lacroix-Desmazes S. 2009. Factor VIII-hydrolyzing IgG in acquired and congenital hemophilia. *FEBS Lett*. 583: 2565-2572.
34. Pavlova A, Delev D, Lacroix-Desmazes S, Schwaab R, Mende M, Fimmers R, Astermark J, Oldenburg J. 2009. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. *J Thromb Haemost*. 7:2006-2015.

35. Mallet VO, Varthaman A, Lasne D, Viard JP, Gouya H, Borgel D, Lacroix-Desmazes S, Pol S. 2009. Acquired protein S deficiency leads to obliterative portal venopathy and to compensatory nodular regenerative hyperplasia in HIV-infected patients. *AIDS* 23:1511-8.
36. Dimitrov JD, Roumenina LT, Andre S, Repesse Y, Atanasov BP, Jacquemin M, Saint-Remy JM, Bayry J, Kaveri SV, Lacroix-Desmazes S. 2010. Kinetics and thermodynamics of interaction of coagulation factor VIII with a pathogenic human antibody. *Mol Immunol.* 47:290-297
37. Dimitrov JD, Dasgupta S, Navarrete AM, Delignat S, Repesse Y, Meslier, Y Planchais C, Teyssandier M, Motterlini R, Bayry J, Kaveri SV, and Lacroix-Desmazes S. 2010. Induction of heme oxygenase-1 in factor VIII-deficient mice reduces the immune response to therapeutic factor VIII. *Blood* 115:2682-2685.
38. Bansal K, Elluru SR, Narayana Y, Chaturvedi R, Patil SA, Kaveri SV, Bayry J, Balaji KN. 2010. PE_PGRS antigens of Mycobacterium tuberculosis induce maturation and activation of human dendritic cells. *J Immunol.* 184:3495-504.
39. Varthaman A, Khallou-Laschet J, Clement M, Fornasa G, Kim HJ, Gaston AT, Dussiot M, Caligiuri G, Herbelin A, Kaveri S, Cantor H, Nicoletti A. 2010. Control of T Cell Reactivation by Regulatory Qa-1-Restricted CD8+ T Cells. *J Immunol.* 184:6585-91.
40. Maddur MS, Vani J, Lacroix-Desmazes S, Kaveri SV and Bayry J. 2010. Contribution of myeloid dendritic cells to type I interferon-induced cytokines and chemokines. *Arthritis Rheum.* 62:2181-2.
41. Olivieri BP, Vasconcellos R, Nóbrega A, Minoprio P, Kaveri SV, Araújo-Jorge TC. 2010. Intravenous immunoglobulin increases survival time in the acute phase of experimental Chagas disease. *Parasite Immunol.* 32:464-9.
42. Mouyna I, Kniemeyer O, Jank T, Loussert C, Mellado E, Aïmanianda V, Beauvais A, Wartenberg D, Sarfati J, Bayry J, Prévost MC, Brakhage A, Strahl S, Huerre M, Latgé JP. 2010. Members of protein O-mannosyltransferase family in *Aspergillus fumigatus* differentially affect growth, morphogenesis and viability. *Mol Microbiol.* 76:1205-1221.
43. Bénard A, Cavailles P, Boué J, Chapey E, Bayry J, Blanpied C, Meyer N, Lamant L, Kaveri SV, Brousset P, Dietrich G. 2010. μ -Opioid receptor is induced by IL-13 within lymph nodes from patients with Sézary syndrome. *J Invest Dermatol.* 130:1337-44.
44. Dimitrov JD, Planchais C, Kang J, Pashov A, Vassilev TL, Kaveri SV, Lacroix-Desmazes S. 2010. Heterogeneous antigen recognition behavior of induced polyspecific antibodies. *Biochem Biophys Res Commun.* 398:266-71.
45. Fornasa G, Groyer E, Clement M, Dimitrov J, Compain C, Gaston AT, Varthaman A, Khallou-Laschet J, Newman DK, Graff-Dubois S, Nicoletti A, Caligiuri G. 2010. TCR stimulation drives cleavage and shedding of the ITIM receptor CD31. *J Immunol.* 184:5485-92.
46. Djoumerska-Alexieva IK, Dimitrov JD, Voynova EN, Lacroix-Desmazes S, Kaveri SV, Vassilev TL. 2010. Exposure of IgG to an acidic environment results in molecular modifications and in enhanced protective activity in sepsis. *FEBS J.* 277:3039-50.

47. Pires AE, Afonso AF, Queirós A, Cabral MS, Porrata L, Markovic SN, Kaveri SV, da Silva MG, João C. 2010. Treatment with polyclonal immunoglobulin during T-cell reconstitution promotes naive T-cell proliferation. *J Immunother.* 33:618-25.
48. Bansal K, Sinha AY, Ghorpade DS, Togarsimalemath SK, Patil SA, Kaveri SV, Balaji KN, Bayry J. 2010. Src homology 3-interacting domain of Rv1917c of Mycobacterium tuberculosis induces selective maturation of human dendritic cells by regulating PI3K-MAPK-NF-kappaB signaling and drives Th2 immune responses. *J Biol Chem.* 285:36511-22.
49. Dimitrov JD, Roumenina LT, Plantier JL, Andre S, Saboulard D, Meslier Y, Planchais C, Jacquemin M, Saint-Remy, JM, Atanasov BP, Kaveri SV, Lacroix-Desmazes S. 2010. A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope. *J Thromb Haemost.* 8:1524-31.
50. Meslier Y, André S, Teyssandier M, Kaveri SV, Lacroix-Desmazes S. 2010. Maternally transferred anti-factor VIII IgG reduce the anti-factor VIII humoral immune response in factor VIII-deficient mice. *Immunology.* 131:549-555.
51. Araujo, L. M, A. Chauvineau, R. Zhu, S. Diem, E. Bourgeois, J. Bayry, M. Daëron, P. Bruhns, S. V. Kaveri & A. Herbelin. 2011. **Cutting Edge:** IVIg inhibits iNKT cell-mediated allergic airway inflammation through FcγRIIIA-dependent mechanisms. *J. Immunol.* 186:3289-3293.
52. Maddur MS, Vani J, Hegde P, Lacroix-Desmazes S, Kaveri S and Bayry J. 2011. Inhibition of differentiation, amplification and function of human Th17 cells by intravenous immunoglobulin. *J Allergy Clin Immunol.* 127:823-830.
53. Bayry J, Fournier EM, Maddur MS, Vani J, Wootla B, Dimitrov JD, Sibénil S, Dimitrov JD, Lacroix-Desmazes S, Berdah M, Carbol Y, Oksenhendler E, Lévy Y, Mouthon L, Sautès-Fridman C, Hermine O and Kaveri SV. 2011. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: A mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. *J Autoimmun.* 36:9-15.
54. Wootla B, Christophe OD, Mahendra A, Dimitrov JD, Repessé Y, Ollivier V, Friboulet A, Borel-Derlon A, Levesque H, Borg JY, Andre S, Bayry J, Calvez T, Kaveri SV, Lacroix-Desmazes S. 2011. Proteolytic antibodies activate factor IX in patients with acquired haemophilia. *Blood* 117:2257-2264.
55. Meslier Y, André S, Dimitrov JD, Delignat S, Bayry J, Kaveri SV, Lacroix-Desmazes S. 2011. Bortezomib delays the onset of factor VIII inhibitors in experimental hemophilia A, but fails to eliminate established anti-factor VIII IgG-producing cells. *J Thromb Haemost.* 9: 719-28.
56. Ghorpade DS, Kaveri SV, Bayry J, Balaji KN. 2011. Co-operative regulation of Notch1-PI3k signaling by NOD1, NOD2 and TLR2 renders enhanced refractoriness to transforming growth factor-β (TGF-β) or cytotoxic T-lymphocyte antigen 4 (CTLA-4) mediated impairment of human dendritic cells maturation. *J Biol Chem.* 286:31347-60.
57. Varthaman A, Clement M, Khallou-Laschet J, Fornasa G, Gaston AT, Dussiot M, Caligiuri G, Cantor H, Kaveri S, Nicoletti A. 2011. Physiological Induction of Regulatory Qa-1-Restricted CD8+ T Cells Triggered by Endogenous CD4+ T Cell Responses. *PLoS One.* 6:e21628.

58. Roumenina LT, Radanova M, Atanasov BP, Popov KT, Kaveri SV, Lacroix-Desmazes S, Frémeaux-Bacchi V, Dimitrov JD. 2011. Heme interacts with c1q and inhibits the classical complement pathway. *J Biol Chem.* 286:16459-69.
59. Barnay-Verdier S, Fattoum L, Borde C, Kaveri S, Gibot S, Maréchal V. 2011. Emergence of autoantibodies to HMGB1 is associated with survival in patients with septic shock. *Intensive Care Med.* 37:957-62.
60. Navarrete AM, Delignat S, Teillaud JL, Kaveri SV, Lacroix-Desmazes S, Bayry J. 2011. CD4+CD25+ regulatory T cell-mediated changes in the expression of endocytic receptors and endocytosis process of human dendritic cells. *Vaccine.* 29:2649-52.
61. Maddur MS, Kaveri SV, Bayry J. 2011. Comparison of different IVIg preparations on IL-17 production by human Th17 cells. *Autoimmun Rev.* 10:809-810.
62. Dimitrov JD, Lacroix-Desmazes S, Kaveri SV. 2011. Important parameters for evaluation of antibody avidity by immunosorbent assay. *Anal Biochem.* 418:149-51.
63. Maddur MS, Hegde P, Sharma M, Kaveri SV, Bayry J. 2011. B cells are resistant to immunomodulation by 'IVIg-educated' dendritic cells. *Autoimmun Rev.* 11:154-6.
64. Pashov A, Delignat S, Bayry J, Kaveri SV. 2011. Enhancement of the affinity of glucocorticoid receptors as a mechanism underlying the steroid-sparing effect of intravenous immunoglobulin. *J Rheumatol.* 38:2275.
65. Delignat S, Repessé Y, Navarrete AM, Meslier Y, Gupta N, Christophe OD, Kaveri SV, Lacroix-Desmazes S. 2011. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A. *Haemophilia* 18:248-254.
66. Hegde P, Maddur MS, Friboulet A, Bayry J, Kaveri SV. 2011. Viscum album Exerts Anti-Inflammatory Effect by Selectively Inhibiting Cytokine-Induced Expression of Cyclooxygenase-2. *PLoS One* 6:e26312.
67. Kang J, Blalock GR, Dimitrov JD. 2011. Thermodynamic analysis of hepatitis C virus vitality in syringes. *J Infect Dis.* 203:1696-7.
68. Pavlovic S, Zdravkovic N, Dimitrov JD, Djukic A, Arsenijevic N, Vassilev TL, Lukic ML. 2011. Intravenous immunoglobulins exposed to heme (heme IVIG) are more efficient than IVIG in attenuating autoimmune diabetes. *Clin Immunol.* 138:162-71.
69. Casulli S, Topçu S, Fattoum L, von Gunten S, Simon H-U, J.L. Teillaud, J. Bayry, S. V. Kaveri, C. Elbim. 2011. A differential concentration-dependent effect of IVIG on neutrophil functions: Relevance for anti-microbial and anti-inflammatory mechanisms. *PLoS ONE* 6: e26469.
70. Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, Badoual C, Gey A, Ravel P, Marcheteau E, Batteux F, Sandoval F, Adotevi O, Chiu C, Garcia S, Tanchot C, Lone YC, Ferreira LCS, Nelson BH, Hanahan D, Fridman WH, Johannes L, Tartour E. 2011. A CCR4 antagonist combined with vaccines induce antigen-specific CD8⁺ T cells and tumor immunity against self antigens. *Blood* 118: 4853-4862.
71. Bayry J, Mouthon L, Kaveri SV. 2012. Intravenous immunoglobulin expands regulatory T cells in

- autoimmune rheumatic disease. *J Rheumatol*. 39:450-1.
72. Fornasa G, Clement M, Groyer E, Gaston AT, Khallou-Laschet J, Morvan M, Guedj K, Kaveri SV, Tedgui A, Michel JB, Nicoletti A, Caligiuri G. 2012. A CD31-derived peptide prevents angiotensin II-induced atherosclerosis progression and aneurysm formation. *Cardiovasc Res*. 94:30-7.
 73. Trinath J, Maddur MS, Kaveri SV, Balaji KN, Bayry J. 2012. Mycobacterium tuberculosis Promotes Regulatory T-Cell Expansion via Induction of Programmed Death-1 Ligand 1 (PD-L1, CD274) on Dendritic Cells. *J Infect Dis*. 205:694-696.
 74. Le Minoux D, Mahendra A, Kaveri S, Limnios N, Friboulet A, Avelle B, Boquet D, Lacroix-Desmazes S, Padiolleau-Lefèvre S. 2012. A novel molecular analysis of genes encoding catalytic antibodies. *Mol Immunol*. 50:160-8.
 75. Maddur MS, Kaveri SV and Bayry J. 2012. Regulation of human dendritic cells by B cells depends on the signals they receive. *Blood* 119:3863-4.
 76. Vani J, Kaveri SV and Bayry J. 2012. Myeloid dendritic cell dysfunction during primary HIV-1 infection is independent of interaction with gp120. *J Infect Dis*. 205:1893-5.
 77. Hegde P, Kaveri SV and Bayry J. 2012. TLR-2 ligand lipomannan from *Mycobacterium tuberculosis* does not stimulate inflammatory cytokines in dendritic cells. *AIDS* 1182-4.
 78. Vani J, Sharma M, Shaila MS, Kaveri SV, Bayry J. 2012. Effect of gp120 on dendritic cell-derived chemokines: relevance for the efficacy of gp120-based vaccines for HIV-1. *Clin Vaccine Immunol* 19:1335-6.
 79. Vitali C, Mingozzi F, Broggi A, Barresi S, Zolezzi F, Bayry J, Raimondi G, Zanoni I, Granucci F. 2012. Migratory and not lymphoid-resident dendritic cells maintain peripheral self-tolerance and prevent autoimmunity via induction of iTreg cells. *Blood* 120:1237-1245.
 80. Othy S, Bruneval P, Topçu S, Dugail I, Delers F, Lacroix-Desmazes S, Bayry J, Kaveri SV. 2012. Effect of IVIg on human dendritic cell-mediated antigen uptake and presentation: Role of lipid accumulation. *J Autoimmun*. 39:168-72
 81. Repessé Y, Dimitrov JD, Peyron I, Moshai EF, Kiger L, Dasgupta S, Delignat S, Marden MC, Kaveri SV, Lacroix-Desmazes S. 2012. Heme binds to factor VIII and inhibits its interaction with activated factor IX. *J Thromb Haemost*. 10:1062-71.
 82. Teyssandier M, Delignat S, Rayes J, Bryckaert M, Jandrot-Perrus M, Kaveri SV, Lacroix-Desmazes S. 2012. Activation state of platelet in experimental severe hemophilia A. *Haematologica* 97:1115-6.
 83. Repessé Y, Dasgupta S, Navarrete AM, Delignat S, Kaveri SV, Lacroix-Desmazes S. 2012. Mannose-sensitive receptors mediate the uptake of factor VIII therapeutics by human dendritic cells. *J Allergy Clin Immunol*. 129:1172-3.
 84. Dimitrov JD, Christophe OD, Kang J, Repessé Y, Delignat S, Kaveri SV, Lacroix-Desmazes S. 2012. Thermodynamic analysis of the interaction of factor VIII with von Willebrand factor. *Biochemistry* 51:4108-16.
 85. Othy S, Topçu S, Kaveri SV, Bayry J. 2012. Effect of CC chemokine receptor 4 antagonism on the

evolution of experimental autoimmune encephalomyelitis. *Proc Natl Acad Sci U S A*. 109:E2412-3.

86. Maddur MS, Sharma M, Hegde P, Lacroix-Desmazes S, Kaveri SV, Bayry J. 2013. Inhibitory effect of IVIG on IL-17 production by Th17 Cells is independent of anti-IL-17 antibodies in the immunoglobulin preparations. *J Clin Immunol*. 33: S62-S66.
87. Teyssandier M, André S, Gupta N, Dasgupta S, Bayry J, Kaveri SV, Lacroix-Desmazes S. 2013. Therapeutic factor VIII does not trigger TLR1.2 and TLR2.6 signalling in vitro.; The ABIRISK consortium. *Haemophilia*. 19:399-402.
88. Ghorpade DS, Holla S, Kaveri SV, Bayry J, Patil SA, Balaji KN. 2013. Sonic hedgehog-dependent induction of microrna 31 and microrna 150 Regulates Mycobacterium bovis BCG-Driven Toll-Like Receptor 2 signaling. *Mol Cell Biol*. 33:543-56.
89. Alsteens D, Aïmanianda V, Hegde P, Pire S, Beau R, Bayry J, Latgé JP, Dufrêne YF. 2013. Unravelling the nanoscale surface properties of chitin synthase mutants of *Aspergillus fumigatus* and their biological implications. *Biophys J*. 105: 320-327.
90. Repessé Y, Peyron I, Dimitrov JD, Dasgupta S, Farrokhi Moshai E, Costa C, Borel-Derlon A, Guillet B, D' Oiron R, Aouba A, Rothschild C, Oldenburg J, Pavlova A, Kaveri SV, Lacroix-Desmazes S. ABIRISK consortium. 2013. Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphism in the HMOX1 promoter. *Haematologica* 98:1650-5
91. Maddur MS, Kaveri SV, Bayry J. 2013. Dual role of CpG-stimulated B cells in the regulation of dendritic cells. *Arthritis Rheum* 65: 2215-2216.
92. Othy S, Hegde P, Topçu S, Sharma M, Maddur MS, Lacroix-Desmazes S, Bayry J, Kaveri SV. 2013. Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1-mammalian target of rapamycin axis. *J Immunol*. 190:4535-41.
93. Trinath J, Hegde P, Balaji KN, Kaveri SV, Bayry J. 2013. Intravenous immunoglobulin-mediated regulation of Notch ligands on human dendritic cells. *J Allergy Clin Immunol*. 131:1255-7.
94. Mahendra A, Peyron I, Dollinger C, Gilardin L, Sharma M, Wootla B, Padiolleau-Lefevre S, Friboulet A, Boquet D, Legendre C, Kaveri SV, Thaunat O, Lacroix-Desmazes S. 2013. IVIg treatment reduces catalytic antibody titers of renal transplanted patients. *PLoS One* 8:e70731.
95. Shevchenko I, Karakhanova S, Soltek S, Link J, Bayry J, Werner J, Umansky V, Bazhin A. 2013. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. *Int J Cancer* 133:98-107.
96. Gupta N, Legoff J, Chamat S, Mercier-Delarue S, Touzelet O, Power UF, Kazatchkine MD, Simon F, Lacroix-Desmazes S, Bayry J, Kaveri SV. 2013. Affinity-purified respiratory syncytial virus antibodies from intravenous immunoglobulin exert potent antibody-dependent cellular cytotoxicity. *PLoS One*. 8:e69390.
97. Frimat M, Tabarin F, Dimitrov JD, Poitou C, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. 2013. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. *Blood* 122:282-92.

98. Trinath J, Hegde P, Sharma M, Maddur MS, Rabin M, Vallat JM, Magy L, Balaji KN, Kaveri SV, Bayry J. 2013. Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. *Blood* 122:1419-27.
99. Sharma M, Hegde P, Aimanianda V, Beau R, Maddur MS, Sénéchal H, Poncet P, Latgé JP, Kaveri S, Bayry J. 2013. Circulating human basophils lack the features of professional antigen presenting cells. *Sci Rep.* 3: 1188.
100. Vani J, Shaila MS, Trinath J, Balaji KN, Kaveri SV, Bayry J. 2013 Mycobacterium tuberculosis cell wall-associated Rv3812 protein induces strong dendritic cell-mediated interferon γ responses and exhibits vaccine potential. *J Infect Dis.* 208:1034-6.
101. Bonduelle O, Yahia N, Siberil S, Benhabiles N, Carrat F, Krivine A, Rozenberg F, Dimitrov J, Kaveri SV, Curjol A, Tindel M, Louet M, Desert F, Launay O, Loulergue P, Badre G, Katlama C, Bricaire F, Samri A, Rousset D, van der Werf S, Jauréguiberry S, Combadiere B. 2013. Longitudinal and integrative biomodeling of effector and memory immune compartments after inactivated influenza vaccination. *J Immunol.* 191:623-31.
102. Sharma M, Kaveri SV, Bayry J. 2013. Human basophils lack the capacity to drive memory CD4+ T cells toward the IL-22 response. *J Allergy Clin Immunol.* 132(6):1457-1458.
103. Rayes J, Roumenina LT, Dimitrov JD, Repessé Y, Ing M, Christophe O, Jokiranta TS, Halbwachs-Mecarelli L, Borel-Derlon A, Kaveri SV, Frémeaux-Bacchi V, Lacroix-Desmazes 2014. The interaction between factor H and VWF increases factor H cofactor activity and regulates VWF prothrombotic status. *Blood* 123:121-125.
104. Pashov AD, Calvez T, Gilardin L, Maillère B, Repessé Y, Oldenburg J, Pavlova A, Kaveri SV, Lacroix-Desmazes S. 2014. In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene. *Haemophilia* 20:176-184.
105. Patil PK, Sajjanar CM, Natarajan C, Bayry J. 2014. Neutralizing antibody responses to foot-and-mouth disease quadrivalent (type O, A, C and Asia 1) vaccines in growing calves with pre-existing maternal antibodies. *Vet Microbiol.* 169:233-235.
106. Djoumerska-Alexieva I, Manoylov I, Dimitrov JD, Tchorbanov A. 2014. Serum or breast milk immunoglobulins mask the self-reactivity of human natural IgG antibodies. *APMIS* 122:329-340.
107. Holla S, Kurowska-Stolarska M, Bayry J, Balaji KN. 2014. Selective inhibition of IFNG-induced autophagy by MIR155 and MIR31-responsive WNT5A and SHH signaling. *Autophagy* 10:311-330.
108. Gupta N, Hegde P, Lecerf M, Nain M, Kalia M, Vrati S, **Bayry J**, Lacroix-Desmazes S, Kaveri SV 2014. Japanese encephalitis virus expands regulatory T cells by increasing the expression of PD-L1 on dendritic cells. *Eur J Immunol.* 44:1363-1374.
109. Holla S, Sharma M, Vani J, Kaveri SV, Balaji KN, Bayry J. 2014. GM-CSF along with IL-4 but not alone is indispensable for the differentiation of human dendritic cells from monocytes. *J Allergy Clin Immunol.* 133:1500-1502.e1.

110. Mahendra A, Gangadharan B, André S, Boudjoghra M, Davi F, Lecerf M, Planchais C, Kaveri SV, Lacroix-Desmazes S, Dimitrov JD. 2014. Cryptic polyreactivity of IgG expressed by splenic marginal zone B-cell lymphoma. *Mol Immunol*. 60:54-61.
111. Othy S, Topçu S, Saha C, Kothapalli P, Lacroix-Desmazes S, Käsermann F, Miescher S, Bayry J, Kaveri SV. 2014. Sialylation is indispensable for reciprocal modulation of helper T lymphocytes by intravenous immunoglobulin in experimental autoimmune encephalomyelitis. *Eur J Immunol*. [Epub ahead of print]
112. Shahsavarian MA, Le Minoux D, Matti KM, Kaveri S, Lacroix-Desmazes S, Boquet D, Friboulet A, Avelle B, Padiolleau-Lefèvre S. 2014. Exploitation of rolling circle amplification for the construction of large phage-display antibody libraries. *J Immunol Methods* [Epub ahead of print]
113. Dalmas E, Venteclef N, Caer C, Poitou C, Cremer I, Aron-Winewsky J, Lacroix-Desmazes S, Bayry J, Kaveri SV, Clément K, André S, Guerre-Millo M. 2014. T cell-derived IL-22 amplifies IL-1 β -driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes. *Diabetes* [Epub ahead of print]
114. Sharma M, Lecerf M, Friboulet A, Kaveri SV, Dissous C, Bayry J. 2014. Mediation of T-helper 17 responses to schistosomes by dendritic cells but not basophils. *J Infect Dis* [Epub ahead of print]
115. Bouhlal H, Martinvalet D, Teillaud JL, Fridman CS, Kazatchkine MD, **Bayry J**, Lacroix-Desmazes S, Kaveri SV. 2014. Natural autoantibodies to Fc γ receptors in intravenous immunoglobulins. *J Clin Immunol*. [Epub ahead of print]
116. Sharma M, Schoindre Y, Gilardin L, Saha C, Benveniste O, Kaveri SV, Bayry J. 2014. Interferon α inhibition by intravenous immunoglobulin is independent of modulation of plasmacytoid dendritic cell population in the circulation. *Arthritis Rheumatol*. [epub ahead of print]
117. Delignat S, Repessé Y, Gilardin L, Dimitrov JD, Lone YC, Kaveri SV, Lacroix-Desmazes S. 2014. Predictive immunogenicity of Refacto® AF. *Haemophilia* [Epub ahead of print]
118. Bayry J, Beaussart A, Dufrêne Y, Sharma M, Bansal K, Kniemeyer O, Aimanianda V, Brakhage A, Kaveri SV, Kwon-Chung KJ, Latge JP, Beauvais A. 2014. Surface structure characterization of *Aspergillus fumigatus* conidia mutated in the melanin synthesis pathway and their human cellular immune response. *Infect Immun*. [in press]
119. Maddur MS, Sharma M, Hegde P, Stephen-Victor E, Pulendran B, Kaveri SV, Bayry J. 2014. Human B cells induce dendritic cell maturation and favor Th2 polarization by inducing OX-40 ligand. *Nature Commun* [in press]

Editorials

1. Bayry J, Kazatchkine MD and Kaveri SV. 2007. Shortage of human intravenous immunoglobulin: reasons and possible solutions. *Nature Clin Pract Neurol (Nat Rev Neurol)*. 3:120-121.
2. Dimitrov JD, Bayry J and Kaveri SV. 2007. Sialylated therapeutic IgG: A sweet remedy for inflammatory diseases? *Nephrol Dial Transplant*. 22:1301-1304

3. Kaveri, S.V. Lacroix-Desmazes, S. and J. Bayry. 2008. Antiinflammatory IgG. *N. Engl. J. Med.* 359: 307-309.
4. Kaveri SV. 2009. Anti-factor VIII Antibodies (Inhibitors) in Hemophilia A: In Dire Need of Basic and Therapeutic Research. *Clin Rev Allergy Immunol.* 37:55-7.
5. Hegde, N.R., M. S Maddur, P. P. Rao, S. V Kaveri and J. Bayry. 2009. Thermostable foot-and-mouth disease virus as a vaccine candidate for endemic countries: a perspective. *Vaccine* 27:2199-201.
6. Bayry J. 2009. CTLA-4: a key protein in autoimmunity. *Nature Rev Rheumatol.* 5:244-245.
7. Maddur MS, Kaveri SV and Bayry J. 2010. Basophils as antigen presenting cells. *Trends Immunol.* 31:45-8
8. Maddur MS, Vani J, Lacroix-Desmazes S, Kaveri SV and Bayry J. 2010. Autoimmunity as a predisposition for infectious diseases. *PLoS Pathogens* 6:e1001077
9. Kaveri SV, Mouthon L and Bayry J. 2010. Basophils and nephritis in lupus. *N Engl J Med.* 363:1080-1082.
10. Bayry J. 2010. TL1A in the inflammatory network in autoimmune diseases. *Nature Rev Rheumatol.* 6: 67-68
11. Bayry J. 2011. New horizons in natural TNF- α antagonist research. *Trends Mol Med.* 17:538-540.
12. Bayry J, Amanianda V, Guijarro JI, Sunde M and Latgé JP. 2012. Hydrophobins-unique fungal proteins. *PLoS Pathog.* 8:e1002700
13. Bazhin A, Bayry J, Umansky V, Werner J and Karakhanova S. 2013. Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer. *Oncoimmunology* 2: e25736.
14. Sharma M, Kaveri SV, Bayry J. 2013. Th17 cells, pathogenic or not? TGF- β 3 imposes the embargo. *Cell Mol Immunol.*10:101-2.
15. Bayry J, Tartour E and Tough DF. 2014. Targeting CCR4 as an emerging strategy for cancer therapy and vaccines. *Trends Pharmacol Sci.* 35:163-165.

Review Articles

1. Bayry J, Lacroix-desmazes S Kazatchkine MD and Kaveri SV. 2007. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: an insight into the rationale and mechanisms of action. *Nature Clin Pract Rheumatol (Nat Rev Rheumatol).* 3:262-272.
2. Bayry J, Sibénil S, Triebel F, Tough DF and Kaveri SV. 2007. Rescuing the CD4+CD25+ regulatory T cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy. *Drug Discov Today* 12:548-552.

3. Negi VS, Elluru S, Sibérel S, Graff-Dubois S, Mouthon L, Kazatchkine MD, Lacroix-Desmazes S, Bayry J and Kaveri SV. 2007. Intravenous Immunoglobulin: An update on the clinical use and mechanisms of action. *J Clin Immunol*. 27:233-245.
4. Elluru S, Vani J, Delignat S, Bloch, MF, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV and Bayry J. 2008. Modulation of human dendritic cell maturation and function by natural IgG antibodies. *Autoimmun Rev*. 7:487-490
5. Vani J, Elluru S, Negi VS, Lacroix-Desmazes S, Kazatchkine MD, Bayary J and Kaveri SV. 2008. Role of natural antibodies in immune homeostasis: IVIg perspective. *Autoimmun Rev*. 7:440-444.
6. Dimitrov JD, Lacroix-Desmazes S, Kaveri SV, Vassilev TL. 2008. Insight into the mechanism of the acquired antibody auto-reactivity. *Autoimmun Rev*. 7:410-4
7. Tha-In T, Bayry J, Metselaar HJ, Kaveri SV and Kwekkeboom J. 2008. Modulation of the cellular immune system by Intravenous Immunoglobulin. *Trends Immunol*. 29:608-15
8. Servettaz A, Guilpain P, Tamas N, Kaveri SV, Camoin L, Mouthon L. 2008. Natural anti-endothelial cell antibodies. *Autoimmun Rev*. 7:426-30.
9. Lacroix-Desmazes S, Navarrete A-M, André S, Bayry J, Kaveri SV and Dasgupta S. 2008. Dynamics of factor VIII interactions determine its immunological fate in hemophilia A. *Blood* 112:240-249.
10. Dimitrov JD, Vassilev TL, Andre S, Kaveri SV, Lacroix-Desmazes S. 2009. Functional variability of antibodies upon oxidative processes. *Autoimmun Rev*. 7:574-8
11. Dasgupta S, Bayry J, André S, Kaveri SV and Lacroix-Desmazes S. 2008. Auditing protein therapeutics “management” by professional APCs: towards prevention of immune responses in replacement therapy. *J Immunol* 181: 1609-1615.
12. Durandy A, Kaveri SV, Kuijpers TW, Basta M, Miescher S, Ravetch JV, Rieben R. 2009. Intravenous immunoglobulins--understanding properties and mechanisms. *Clin Exp Immunol*. 158 Suppl 1:2-13.
13. Wootla B, Rao DN, Friboulet A, Uda T, Lacroix-Desmazes S, Kaveri SV. 2009. Varied Immune Response to FVIII: Presence of Proteolytic Antibodies Directed to Factor VIII in Different Human Pathologies. *Clin Rev Allergy Immunol*. 37:97-104
14. André S, Meslier Y, Dimitrov JD, Repessé Y, Kaveri SV, Lacroix-Desmazes S, Dasgupta S. 2009. A Cellular Viewpoint of Anti-FVIII Immune Response in Hemophilia A. *Clin Rev Allergy Immunol*. 7:105-13
15. Kaveri S, Gringeri A, Heisel-Kurth M, Kreuz W. 2009. Inhibitors in haemophilia A: the role of VWF/FVIII concentrates--a meeting report. *Haemophilia* 152:587-91
16. André S, D. F. Tough, S. Lacroix-Desmazes, S. V Kaveri and J. Bayry. 2009. Surveillance of antigen-presenting cells by CD4+CD25+ regulatory T cells in autoimmunity: immunopathogenesis and therapeutic implications. *Am J. Pathol*. 174:1575-1887.
17. Lutz, H.U. C.J. Binder and S. V. Kaveri . 2009. Naturally occurring auto-antibodies in homeostasis and disease. *Trends Immunol* 30:43-51.

18. Aïmanianda V, Haensler J, Lacroix-Desmazes S, Kaveri SV and Bayry J. 2009. Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants. *Trends Pharmacol Sci.* 30: 287-295
19. Maddur MS, Othy S, Hegde P, Vani J, Lacroix-Desmazes S, Bayry J, Kaveri SV. 2010. Immunomodulation by intravenous immunoglobulin: role of regulatory T cells. *J Clin Immunol.* 30 Suppl 1:S4-8
20. Galeotti C, Bayry J, Kone-Paut I and Kaveri SV. 2010. Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. *Autoimmun Rev.* 9:441-8.
21. Navarrete AM, Dasgupta S, Teyssandier M, Repesse Y, Delignat S, Andre S, Bayry J, Kaveri SV, Lacroix-Desmazes S. 2010. Endocytic receptor for pro-coagulant factor VIII: Relevance to inhibitor formation. *Thromb Haemost.* 104:1093-8
22. Kaveri S, Mannucci PM, Kurth MH, Ewing N, Kessler CM, Nugent DJ, Gomperts ED. 2011. von Willebrand factor: what is its role in the immune response in haemophilia? *Haemophilia* 17:e235-38.
23. Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J. 2011. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. *Clin Exp Immunol.* 164 Suppl 2:2-5.
24. Bayry, J, V. S. Negi and S.V. Kaveri. 2011. Intravenous immunoglobulin therapy in rheumatic diseases. *Nature Rev Rheumatol.* 7:349-359.
25. Dimitrov JD, Kazatchkine MD, Kaveri SV, Lacroix-Desmazes S. 2011. "Rational vaccine design" for HIV should take into account the adaptive potential of polyreactive antibodies. *PLoS Pathog.* 7:e1002095
26. Wootla B, Lacroix-Desmazes S, Warrington AE, Bieber AJ, Kaveri SV, Rodriguez M. 2011. Autoantibodies with enzymatic properties in human autoimmune diseases. *J Autoimmun.* 37:144-50
27. Hegde NR, Kaveri SV, Bayry J. 2011. Recent advances in the administration of vaccines for infectious diseases: microneedles as painless delivery devices for mass vaccination. *Drug Discov Today* 23-24:1061-8
28. Kaveri SV. 2012. Intravenous immunoglobulin: Exploiting the potential of natural antibodies. *Autoimmun Rev.* 11:792-794.
29. Mahendra A, Padiolleau-Lefevre S, Kaveri SV, Lacroix-Desmazes S. 2012. Do proteolytic antibodies complete the panoply of the autoimmune response in acquired haemophilia A? *Br J Haematol.* 156:3-12.
30. Kaveri SV, Silverman GJ, Bayry J. 2012. Natural IgM in immune equilibrium and harnessing their therapeutic potential. *J Immunol.* 188:939-45.
31. Maddur MS, Miossec P, Kaveri SV and Bayry J. 2012. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases and therapeutic strategies. *Am J Pathol.* 181:8-18.
32. Pere H, Tanchot C, Bayry J, Terme M, Taieb J, Badoual C, Adotevi O, Merillon N, Marcheteau E,

- Quillien V, Banissi C, Carpentier A, Sandoval F, Nizard M, Quintin-Colonna F, Kroemer G, Fridman WH, Zitvogel L, Oudard S and Tartour E. 2012. Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. *Oncoimmunology* 1:326-333
33. Mahendra A, Sharma M, Rao DN, Peyron I, Planchais C, Dimitrov JD, Kaveri SV, Lacroix-Desmazes S. 2013. Antibody-mediated catalysis: Induction and therapeutic relevance. *Autoimmun Rev.* 12:648-52.
34. Kaveri S. 2013. Advances in the treatment of primary and secondary immune deficiencies. *Curr Opin Allergy Clin Immunol.* 13 Suppl 2:S51-2.
35. Buttman M, Kaveri S, Hartung HP. 2013. Polyclonal immunoglobulin G for autoimmune demyelinating nervous system disorders. *Trends Pharmacol Sci.* 34:445-57.
36. Dimitrov JD, Planchais C, Roumenina LT, Vassilev TL, Kaveri SV, Lacroix-Desmazes S. 2013. Antibody polyreactivity in health and disease: statu variabilis. *J Immunol.* 191:993-9.
37. Dimitrov JD, Kaveri SV, Lacroix-Desmazes S. 2014. Thermodynamic stability contributes to immunoglobulin specificity. *Trends Biochem Sci.* [Epub ahead of print].
38. Gilardin L, Bayry J, Kaveri SV. 2014. Intravenous immunoglobulin: an update on clinical evidence and immunomodulatory effects. *CMAJ* [in press]